FOXO3 and pancreatic neoplasm: In PDACs overexpressing 67LR, a phosphodiesterase inhibitor (PDE3) and epigallocatechin 3-O-gallate (EGCG) in combination significantly suppressed the FOXO3-CD44 axis in pancreatic cancer stem cells [167].